C50.A2 — Malignant inflammatory neoplasm of left breast
C50.A2 is a billable, specific ICD-10-CM code for malignant inflammatory neoplasm of left breast. It is valid for submission on a claim.
Risk adjustment
C50.A2 risk-adjusts. Under the CMS-HCC V28 model it maps to these categories:
- HCC 22 Bladder, Colorectal, and Other Cancers0.363 RAF
- HCC 23 Prostate, Breast, and Other Cancers and Tumors0.186 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C50.A2 is named in 45 Medicare coverage policies — 45 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®, Wyost®, Ospomyv™,Xbryk™,Bomyntra®, Conexxence®, Stoboclo®, Osenvelt®,Bildyos®, Bilprevda®)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
Code history
What changed, and when. Derived by diffing consecutive CMS release files — which matters when you are defending a code assigned under an earlier edition.
- addedFY2024-FY2026
Malignant inflammatory neoplasm of left breast
Related codes at this level
Codes that share C50.A. If C50.A2 is not quite right, the correct code is usually one of these.
Questions about C50.A2
- Is C50.A2 a billable ICD-10-CM code?
- Yes. C50.A2 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C50.A2 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of breast (C50).